Bayer AG is a German multinational pharmaceutical and life sciences company headquartered in Leverkusen, Germany, founded in 1863. It is one of the world's largest pharmaceutical companies with significant operations in cardiovascular, oncology, women's health, and neuroscience[1].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| Elenbecestat (E2609) | BACE inhibitor | Alzheimer's Disease | Phase 3 | Discontinued (2019) |
| Molidustat (BAY 85-3934) | HIF-PH inhibitor | Anemia in CKD | Approved (Japan/EU) | Marketed |
| Finerenone (BAY 94-8862) | MR antagonist | Diabetic Kidney Disease | Approved | Marketed |
| Selatoclax (BAY 1142529) | MCL-1 inhibitor | AML/MDS | Phase 1/2 | Active |
| Larotrectinib (LOXO-101) | TRK inhibitor | Solid tumors | Approved | Marketed |
| Vitrakvi (LOXO-101) | TRK inhibitor | Solid tumors | Approved | Marketed |
| Navitoclax (ABT-263) | BCL-2/XL inhibitor | Myelofibrosis | Phase 2 | Active |
Bayer's key technologies include:
Bayer had an active Alzheimer's disease program with elenbecestat (E2609), a BACE inhibitor developed in partnership with Eisai. The program was discontinued in 2019 due to safety concerns (worsening of cognitive function in some patients), a class effect seen across BACE inhibitors[2].
Current neuroscience focus includes: